Melanoma
Conditions
Brief summary
The hypothesis is that PD-L1\[Programmed Death-Ligand 1\] labeling in exosomes could be a biomarker of disease progression in melanoma. The rate of circulating exosomes, their size and the exosomal expression of PD-L1 could be correlated with the stage of the disease, the response to treatment and/or the prognosis of patients. In this study, blood samples (EDTA tubes taken as part of routine care at Besançon University Hospital) and associated clinical data are reused.
Interventions
None listed
Sponsors
Centre Georges Francois Leclerc
Centre Hospitalier Universitaire de Besancon
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Melanoma patients admitted in Besançon University Hospital * exigible for immunotherapy such as anti PD-L1/PD-1 * Age ≥18 years * Affiliation to a social security system,
Exclusion criteria
* Minor patients * Patients who have expressed their opposition to the reuse of their data and biological samples
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quantification of circulating exosomes | Day 1 | Dosage of proteic biomarkers in circulating exosomes, plasma and tumor tissues. Blood samples were taken in standard care, before initiation of immunotherapy and then during disease follow-up until progression and tumor evaluation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PDL1 marking | Day 1 | Compare PD-L1 labeling in exosomes to PD-L1 labeling in plasma and in tumor tissue. Blood samples were taken in standard care, before initiation of immunotherapy and then during disease follow-up until progression and tumor evaluation |
| Other proteins detection | Day 1 | Identify other proteins of interest in circulating exosomes. Blood samples were taken in standard care, before initiation of immunotherapy and then during disease follow-up until progression and tumor evaluation. |
| Determine whether the initial exosome concentration (at T0) is associated with a response to treatment. | Day 1 | Dosage of PD-L1 in circulating exosomes. Blood samples were taken in standard care, before initiation of immunotherapy and then during disease follow-up until progression and tumor evaluation |
Countries
France
Outcome results
None listed